Showing results (181-190 of 259) with videos related to
Sort By:
Pageof 26
Blood|February 7, 2009
International prognostic scoring system for Waldenstrom macroglobulinemiaPierre Morel, Alain Duhamel, Paolo Gobbi, et al.Cancer Research|April 17, 2004
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implicationsYu-Tzu Tai, Laurence P Catley, Constantine S Mitsiades, et al.Oncotarget|April 21, 2017
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventionsAntonio Sacco, Adriano Fenotti, Loredana Affò, et al.Leukemia & Lymphoma|June 11, 2011
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cellsJenny Y Sun, Hsiuyi Tseng, Lian Xu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM TrialJudith Trotman, Christian Buske, Alessandra Tedeschi, et al.Proceedings of the National Academy of Sciences of the United States of America|October 23, 2002
Molecular sequelae of proteasome inhibition in human multiple myeloma cellsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 2, 2002
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applicationsSteven P Treon, Linda M Pilarski, Andrew R Belch, et al.Blood|November 18, 2021
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WMAbdul Hamid Bazarbachi, Hervé Avet-Loiseau, Raphael Szalat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.Blood|February 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemiaHao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu, et al.Pageof 26